Rezdiffra (Resmetirom) for NASH F2-F3: Risks, Tradeoffs, and What the Evidence Shows

Is Resmetirom Actually Off-Label for NASH F2-F3?

No. Resmetirom is FDA-approved for this exact use. The confusion stems from the disease name change and the drug's novelty. In March 2024, the FDA granted Rezdiffra accelerated approval for adults with noncirrhotic NASH (now called MASH) and moderate to advanced liver fibrosis, corresponding to fibrosis stages F2 and F3 [2]. This was a landmark decision. No drug had ever been approved to treat this disease before.

The approval rests on histological surrogate endpoints, not on long-term clinical outcomes like reduction in cirrhosis progression or liver-related mortality. That distinction matters. Accelerated approval means the FDA accepted the surrogate data as "reasonably likely to predict clinical benefit" while requiring a confirmatory trial [2]. The MAESTRO-OUTCOMES trial (NCT05500222) is that confirmatory study, evaluating whether resmetirom reduces progression to cirrhosis, liver decompensation, and death over a longer follow-up period [3]. If confirmatory data do not support clinical benefit, the FDA can withdraw approval.

So while the prescription itself is on-label for F2-F3 MASH patients, prescribers and patients should understand that the evidence base supporting long-term outcomes remains incomplete. The drug is approved. The proof that it prevents end-stage liver disease is still being collected.

MAESTRO-NASH Trial: What the Phase 3 Data Show

The MAESTRO-NASH trial is the largest randomized controlled study of resmetirom and the foundation for its approval. Published in the New England Journal of Medicine in 2024, this Phase 3 trial enrolled 966 adults with biopsy-confirmed NASH and fibrosis stages F1B through F3, though the FDA approval applies specifically to F2-F3 [1].

Patients received resmetirom 80 mg (for body weight <100 kg), resmetirom 100 mg (for body weight ≥100 kg), or placebo once daily. The trial measured two co-primary endpoints at 52 weeks, both assessed by liver biopsy.

NASH resolution without worsening fibrosis was achieved by 25.9% of patients on 80 mg and 29.9% on 100 mg, compared with 9.7% on placebo (P<0.001 for both comparisons) [1]. Fibrosis improvement by at least one stage without worsening of the NAFLD Activity Score occurred in 24.2% on 80 mg and 25.9% on 100 mg versus 14.2% on placebo (P<0.001 for 100 mg; P=0.0002 for 80 mg) [1].

These numbers are clinically meaningful but require context. Roughly 70-75% of treated patients did not achieve NASH resolution, and about 74% did not see fibrosis improvement. The absolute risk reduction for fibrosis improvement was approximately 10-12 percentage points over placebo. Resmetirom is not a cure. It shifts the odds in the right direction for a meaningful subset of patients.

The trial also showed consistent reductions in hepatic fat content measured by MRI-PDFF. Patients on resmetirom 100 mg had a relative reduction of approximately 51% in liver fat at week 52 versus 15% for placebo [1]. Liver enzyme reductions were also significant: ALT fell by a mean of 25-30% from baseline in the active treatment arms [4].

How Resmetirom Works: The THR-β Mechanism

Resmetirom is a selective agonist of thyroid hormone receptor beta (THR-β), which is predominantly expressed in the liver [5]. This selectivity is the key to its safety profile. Thyroid hormones regulate hepatic lipid metabolism, and activating THR-β increases mitochondrial fatty acid oxidation, reduces de novo lipogenesis, and lowers circulating LDL cholesterol and triglycerides [5].

The selectivity for THR-β over THR-α is what separates resmetirom from simply giving patients thyroid hormone. THR-α predominates in the heart, bone, and central nervous system. Activating it causes tachycardia, bone loss, and anxiety. Resmetirom has roughly 28-fold selectivity for THR-β over THR-α in binding assays, which explains why cardiac and bone side effects have not been a major signal in trials [5].

Lipid effects are clinically notable. In MAESTRO-NASH, resmetirom 100 mg reduced LDL cholesterol by approximately 16% and triglycerides by about 20% [1]. For patients with MASH who often carry overlapping cardiovascular risk, these lipid improvements could provide secondary benefit, though this has not been proven in an outcomes trial.

Dr. Stephen Harrison, the lead MAESTRO-NASH investigator, stated: "Resmetirom targets the liver specifically, which is why we see the metabolic effects without the systemic thyroid toxicity that has limited earlier approaches" [1].

Side Effects and Safety Concerns

The side-effect profile of resmetirom is dominated by gastrointestinal symptoms. These are common, usually mild to moderate, and tend to diminish over the first 4-12 weeks of treatment.

Diarrhea occurred in 27% of patients on 80 mg and 33% on 100 mg, versus 14% on placebo in MAESTRO-NASH [1]. Most episodes were grade 1-2 and self-limited. Nausea affected 15% on 80 mg and 22% on 100 mg versus 11% on placebo. Abdominal distension and decreased appetite were also more common in active treatment arms [4].

Gallbladder events are the more concerning safety signal. Cholelithiasis (gallstones) and cholecystitis occurred at roughly twice the rate in the resmetirom group compared to placebo during the 52-week trial period [1]. The mechanism likely relates to increased hepatic cholesterol secretion into bile, a downstream effect of THR-β activation. Patients with a history of gallbladder disease need careful risk-benefit discussion before starting treatment.

The FDA label includes a warning about potential hepatotoxicity [2]. While resmetirom generally lowers ALT and AST, isolated cases of clinically significant liver enzyme elevation occurred during trials. The prescribing information requires liver function testing before initiation, during dose titration, and periodically thereafter.

Bone density is a theoretical concern with any thyroid-axis drug. The MAESTRO-NASH 52-week data did not show significant bone mineral density loss, but longer-term data are needed [1]. The American Association for the Study of Liver Diseases (AASLD) practice guidance notes: "Clinicians should monitor patients on resmetirom for thyroid function abnormalities, gallbladder disease, and hepatotoxicity, with baseline and periodic laboratory assessments" [6].

Drug interactions deserve attention. Resmetirom can reduce the efficacy of levothyroxine by altering thyroid hormone metabolism, and it interacts with certain statins through effects on OATP1B1/1B3 transporters [4]. Patients on simvastatin or rosuvastatin may need dose adjustments. The prescribing information recommends limiting simvastatin to 20 mg daily when co-administered with resmetirom.

Who Is a Good Candidate for Resmetirom?

The approved population is adults with noncirrhotic MASH and liver fibrosis stages F2 or F3, confirmed by biopsy or a validated noninvasive combination of biomarkers and imaging. The label does not require biopsy for initiation, though the trial used biopsy-confirmed disease [2].

Good candidates typically share several characteristics. They have documented steatohepatitis with intermediate fibrosis. They have not responded adequately to lifestyle modification after 6-12 months. They do not have decompensated cirrhosis. They are not pregnant or planning pregnancy.

Patients who are less appropriate for resmetirom include those with F0-F1 fibrosis (not approved), F4 fibrosis or cirrhosis (excluded from the key trial and not approved), or active gallbladder disease. Patients with thyroid disorders need careful evaluation because the drug's mechanism directly engages thyroid hormone receptors.

A practical consideration: many patients with MASH remain undiagnosed until they reach advanced fibrosis. The FIB-4 index, a simple calculation using age, AST, ALT, and platelet count, can help identify patients with intermediate-to-high fibrosis risk. A FIB-4 score ≥1.3 warrants further evaluation with transient elastography or enhanced liver fibrosis (ELF) testing [7]. Patients identified through this cascade who meet criteria for F2-F3 disease are the target population for resmetirom.

Risks vs. Tradeoffs: A Practical Framework

The decision to start resmetirom involves weighing incomplete evidence against a progressive disease that had no pharmacotherapy until 2024. MASH with F2-F3 fibrosis is not benign. Left untreated, approximately 20-30% of patients with F3 fibrosis progress to cirrhosis within 5-10 years, and some will develop hepatocellular carcinoma or require liver transplantation [8].

The tradeoffs break down along several axes.

Efficacy uncertainty. The 52-week histological data are encouraging but do not yet prove that resmetirom prevents cirrhosis, liver failure, or death. The number needed to treat (NNT) for one additional patient to achieve NASH resolution is approximately 5-6 [1]. That is a reasonable NNT for a disease with serious long-term consequences, but the clinical relevance of histological improvement as a surrogate depends on confirmatory data from MAESTRO-OUTCOMES.

Cost. At approximately $47,400 per year list price, resmetirom represents a significant financial commitment. Insurance coverage remains variable. Some commercial insurers require prior authorization with documentation of fibrosis stage, failed lifestyle intervention, and elevated liver enzymes. Medicare Part D coverage policies vary by plan [9].

GI tolerability. One in three patients on the 100 mg dose will experience diarrhea. For patients already managing GI issues from metformin, GLP-1 receptor agonists, or other medications, adding another source of GI side effects may reduce treatment adherence. Starting at 60 mg for the first two weeks and titrating up, as recommended in the label, helps mitigate early GI intolerance [4].

Duration of therapy. There is no defined stopping point. The clinical trial data cover 52 weeks, with ongoing open-label extensions. Whether patients can safely discontinue after achieving histological improvement, or whether fibrosis recurs upon stopping, is unknown. The current assumption is that treatment is indefinite for patients who respond.

Gallbladder risk. For patients with prior cholelithiasis, cholecystectomy, or known biliary sludge, the incremental gallbladder risk from resmetirom may tip the balance against use.

Monitoring Requirements During Treatment

Prescribers initiating resmetirom should follow a structured monitoring protocol based on the prescribing information and AASLD guidance [4][6].

Before starting treatment: obtain baseline liver function tests (ALT, AST, total bilirubin, alkaline phosphatase), a lipid panel, thyroid function tests (TSH, free T4), and assess for gallbladder disease history. A pregnancy test is recommended for women of childbearing potential.

During dose titration (weeks 1-12): repeat liver function tests at week 4, week 8, and week 12. The prescribing information recommends holding the drug if ALT or AST rises above 5 times the upper limit of normal, or above 3 times ULN with symptoms or elevated bilirubin [4].

Ongoing monitoring: liver function tests every 3-6 months, lipid panel every 6-12 months, and TSH annually or if symptoms of thyroid dysfunction develop. Gallbladder symptoms (right upper quadrant pain, fat intolerance, nausea after meals) should prompt abdominal ultrasound.

Clinicians managing patients on resmetirom should document the fibrosis stage at baseline and consider reassessment with noninvasive tools (vibration-controlled transient elastography or MRE) at 12 and 24 months to evaluate treatment response. Repeat biopsy is not routinely recommended outside of clinical trials but may be appropriate in selected cases where noninvasive results are discordant with clinical trajectory.

What Happens If MAESTRO-OUTCOMES Fails?

This question is worth addressing directly. Accelerated approval carries a regulatory condition: if the confirmatory trial does not demonstrate clinical benefit, the FDA can initiate proceedings to withdraw approval [2]. This has happened before with other drugs. Aducanumab (Aduhelm) for Alzheimer's disease is a well-known example where post-marketing confirmation proved contentious.

For patients currently on resmetirom, withdrawal of approval would not necessarily mean the drug is ineffective. It would mean the evidence did not meet the FDA's threshold for confirming long-term benefit. The histological improvements observed in MAESTRO-NASH would still be real. But insurance coverage would likely evaporate, and prescribers would face difficult conversations about continuing an unapproved therapy.

The MAESTRO-OUTCOMES trial is expected to report primary results by 2027-2028 [3]. Until then, patients and prescribers are making a calculated bet that histological improvement translates to fewer liver-related clinical events. Based on the natural history data and the strength of the surrogate endpoint association, most hepatologists consider this a reasonable bet for patients with F2-F3 disease and active steatohepatitis [6].

The Broader Treatment Context

Resmetirom does not exist in a vacuum. Lifestyle modification (weight loss of 7-10% body weight through diet and exercise) remains the foundation of MASH management and can produce NASH resolution rates of 40-50% in patients who achieve and sustain that weight loss [10]. GLP-1 receptor agonists like semaglutide have shown promise for NASH in Phase 2 trials, with semaglutide 0.4 mg daily producing NASH resolution in 59% of patients versus 17% on placebo in a 72-week biopsy study (N=320), though no GLP-1 agonist carries an FDA indication for NASH [11].

Pioglitazone, a thiazolidinedione used off-label for NASH, has over 15 years of data showing histological benefit in non-diabetic and diabetic NASH patients [12]. Its side-effect profile (weight gain, edema, fracture risk) limits its appeal, but it costs under $50 per month. Vitamin E (800 IU/day) showed benefit in the PIVENS trial for non-diabetic NASH patients but carries concerns about long-term use, including a possible increase in prostate cancer risk [13].

Resmetirom's advantage is its targeted hepatic mechanism and favorable metabolic side-effect profile (lipid improvement rather than weight gain). Its disadvantage is cost, novelty, and the absence of long-term outcomes data. The choice between resmetirom and these alternatives depends on the individual patient's fibrosis stage, metabolic comorbidities, tolerance for GI side effects, and insurance coverage.

The standard starting dose for patients weighing <100 kg is 80 mg daily, escalated from 60 mg over two weeks; patients weighing ≥100 kg start at 100 mg daily with the same titration [4].